2025-07-30 09:00
publication
2025-07-30 09:00
The reduction of the year -round financial forecast led to the rapid discount of the Novo Nordisk campaign. The values of the manufacturer Ozmpic became a cheaper by 23%, deepening the inheritance trend for nearly a year.
During the Tuesday session, the Novo Nordisk rate fell by 23.1%, descending to the level of 346.90 crowns. At Wall Street, the Danish concern raised a decrease by 21.8% and reached the price of USD 53.94. This is a spectacular discount for the conditions of a pharmaceutical giant with a market value approaching a quarter trillion dollars.
The catalyst for the Tuesday discount of the manufacturer Ozmpic was the reduction of this year's financial forecasts by the Management Board. Novo Nordisk now expects sales increases only by 8-14% relative to 13-21% expected earlier. The forecast operational profit for 2025 is to increase by 10-16%, clearly less than the previously assumed growth by 16-24%. It was the second reduction of Novo Nordisk financial forecasts this year.
Advertisement
– This is a significant, wide correction of forecasts. What was the worst scenario before has now become the best. That is why the actions react so violently – says Lars Hytting, an investment strategist at Arthascope quoted by “Puls Biznesu”.
The Danish company also warned investors that in the second half of the year it expects a slower increase in revenues primarily due to the weaker sales of Wegova on the American market. Also Ozmpic- the currently most famous product of the Danish corporation- loses market shares as a result of increasing competition. Novo Nordisk also struggles with the competition from the so -called complex drugs that are the form of imitation of the original preparation.
– I'm shocked. Not only the American market is under pressure. It seems that Novo is under pressure on almost all markets – said investor Peter Bækgaard, a former stock broker in the USA, and in the 90s, head of the Investor Relationship Department Novo Nordisk overseas quoted by “Puls Biznesu”.
Over the previous months, Novo Nordisk shareholders could already get used to the decrease in the value of their qualities. In August last year, the shares of the Danish company on Wall Street were recorded after nearly $ 140. Since then, they have been able to get over 60%.
The latest history of Novo Nordisk is therefore the history of a spectacular rise and equally fast fall. On the wave of ozmpic fashion, the shares of the Danish company increased from USD 20 in 2018 to almost USD 140 in the summer of 2024. Many people in the West believed that semaglutide patented by the Danes would easily and quickly solve obesity problems. However, this did not happen. After a few years, it turned out that “wonderful” slimming drugs carry a lot of serious side effects.
In addition, a competition has appeared on the market offering similar – or maybe even better – products than Novo Nordisk. In addition, the future of the preparation itself is uncertain. All this meant that the shares until recently the most valuable company in Europe were overestimated by more than half for the previous 12 months. And no one can guarantee that this is the end of the downward trend.
KK
